Recurrent GBM brain tumors with few mutations respond best to immunotherapy – Duke Department of Neurology

Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after theyve grown back, enabling up to 20% of patients to live well beyond predicted survival times.
What causes this effect has long been the pursuit of researchers hoping to harness immunotherapies to extend more lives.
New insights from a team led by Dukes Preston Robert Tisch Brain Tumor Center, including the Neurology Department’s Katherine Peters, MD, PhD, Dina Randazzo,…

Click here to view the original article.